Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 04-May-23 7:44 AM View:  | Murray Richard /ca/ Director | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Disposition (change in control) | 188,778 | -- | -- | (100%) 188.78K to 1 | |
| 05-May-23 4:37 PM View: | Tang Kevin C Director 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Disposition (change in control) | 5,300,090 | $1.85 | $9,805,160.00 | (100%) 5.31M to 10.0K | |
| 04-May-23 7:44 AM View: | Kamen Robert Director | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Disposition (change in control) | 33,875 | -- | -- | (100%) 33.88K to 0 | |
| 04-May-23 7:44 AM View: | Karsen Perry A Director | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Disposition (change in control) | 5,000 | -- | -- | (100%) 5.0K to 0 | |
| 04-May-23 7:43 AM View: | Drapkin Kimberlee C President, CFO and Treasurer | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Disposition (change in control) | 66,018 | -- | -- | (100%) 66.02K to 0 | |
| 05-May-23 4:38 PM View: | Concentra Biosciences, LLC 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Acquisition (other) | 10,000 | $9,737.70 | $97,377,000.00 | 100% 0 to 10.0K | |
| 05-May-23 4:37 PM View: | Tang Kevin C Director 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Acquisition (other) Duplicate | 10,000 | $9,737.70 | $97,377,000.00 | < 1% 5.3M to 5.31M | |
| 04-May-23 7:44 AM View: | Kamen Robert Director | Jounce Therapeutics, Inc. (JNCE) | 03-May-23 | Disposition (change in control) | 60,975 | -- | -- | (64%) 94.85K to 33.88K | |
| 06-Apr-23 4:37 PM View: | Murray Richard /ca/ Director | Jounce Therapeutics, Inc. (JNCE) | 04-Apr-23 | Sale (Planned) | 39,228 | $1.85 | $72,571.80 | (17%) 228.01K to 188.78K | |
| 14-Mar-23 8:39 PM View: | Tang Kevin C 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 14-Mar-23 | Purchase | 20,286 | $1.02 | $20,651.10 | < 1% 5.28M to 5.3M | |
| 14-Mar-23 8:39 PM View: | Tang Kevin C 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 13-Mar-23 | Private Purchase | 65,701 | $0.99 | $65,306.80 | 1% 5.21M to 5.28M | |
| 11-Jan-23 8:30 PM View: | Drapkin Kimberlee C CFO and Treasurer | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-23 | Sale | 7,781 | $1.12 | $8,714.72 | (11%) 73.8K to 66.02K | |
| 11-Jan-23 8:33 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-23 | Sale | 5,126 | $1.12 | $5,741.12 | (5%) 108.54K to 103.42K | |
| 11-Jan-23 8:32 PM View: | Murray Richard /ca/ CEO and President Director | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-23 | Sale | 24,879 | $1.12 | $27,864.50 | (10%) 252.89K to 228.01K | |
| 11-Jan-23 8:29 PM View: | Cole Hugh M Chief Operating Officer | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-23 | Sale | 9,182 | $1.12 | $10,283.80 | (8%) 119.26K to 110.08K | |
| 11-Jan-23 8:32 PM View: | Murray Richard /ca/ CEO and President Director | Jounce Therapeutics, Inc. (JNCE) | 09-Jan-23 | Sale | 20,191 | $1.10 | $22,210.10 | (7%) 273.08K to 252.89K | |
| 11-Jan-23 8:29 PM View: | Cole Hugh M Chief Operating Officer | Jounce Therapeutics, Inc. (JNCE) | 09-Jan-23 | Sale | 7,452 | $1.10 | $8,197.20 | (6%) 126.72K to 119.26K | |
| 11-Jan-23 8:30 PM View: | Drapkin Kimberlee C CFO and Treasurer | Jounce Therapeutics, Inc. (JNCE) | 09-Jan-23 | Sale | 6,315 | $1.10 | $6,946.50 | (8%) 80.11K to 73.8K | |
| 11-Jan-23 8:33 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 09-Jan-23 | Sale | 4,159 | $1.10 | $4,574.90 | (4%) 112.7K to 108.54K | |
| 03-Aug-22 8:29 PM View: | Cole Hugh M Chief Operating Officer | Jounce Therapeutics, Inc. (JNCE) | 01-Aug-22 | Grant | 20,000 | -- | -- | 19% 106.72K to 126.72K | |
| 03-Feb-22 7:38 PM View: | Drapkin Kimberlee C CFO and Treasurer | Jounce Therapeutics, Inc. (JNCE) | 01-Feb-22 | Grant | 27,500 | -- | -- | 52% 52.61K to 80.11K | |
| 03-Feb-22 7:38 PM View: | Cole Hugh M Chief Business Officer | Jounce Therapeutics, Inc. (JNCE) | 01-Feb-22 | Grant | 42,500 | -- | -- | 66% 64.22K to 106.72K | |
| 03-Feb-22 7:36 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 01-Feb-22 | Grant | 27,500 | -- | -- | 32% 85.2K to 112.7K | |
| 03-Feb-22 7:37 PM View: | Murray Richard /ca/ CEO and President Director | Jounce Therapeutics, Inc. (JNCE) | 01-Feb-22 | Grant | 87,500 | -- | -- | 47% 185.58K to 273.08K | |
| 11-Jan-22 8:55 PM View: | Cole Hugh M Chief Business Officer | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-22 | Market Sale | 6,205 | $6.65 | $41,263.20 | (9%) 70.42K to 64.22K | (2%) |
| 11-Jan-22 8:56 PM View: | Drapkin Kimberlee C CFO and Treasurer | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-22 | Market Sale | 8,222 | $6.65 | $54,676.30 | (14%) 60.84K to 52.61K | (2%) |
| 11-Jan-22 8:57 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-22 | Market Sale | 5,378 | $6.65 | $35,763.70 | (6%) 90.58K to 85.2K | (2%) |
| 11-Jan-22 8:57 PM View: | Murray Richard /ca/ CEO and President Director | Jounce Therapeutics, Inc. (JNCE) | 10-Jan-22 | Market Sale | 23,924 | $6.65 | $159,095.00 | (11%) 209.5K to 185.58K | (2%) |
| 11-Jan-22 8:55 PM View: | Cole Hugh M Chief Business Officer | Jounce Therapeutics, Inc. (JNCE) | 07-Jan-22 | Market Sale | 3,468 | $7.30 | $25,316.40 | (5%) 73.89K to 70.42K | 7% |
| 11-Jan-22 8:56 PM View: | Drapkin Kimberlee C CFO and Treasurer | Jounce Therapeutics, Inc. (JNCE) | 07-Jan-22 | Market Sale | 4,595 | $7.30 | $33,543.50 | (7%) 65.43K to 60.84K | 7% |
| 11-Jan-22 8:57 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 07-Jan-22 | Market Sale | 3,005 | $7.30 | $21,936.50 | (3%) 93.58K to 90.58K | 7% |
| 11-Jan-22 8:57 PM View: | Murray Richard /ca/ CEO and President Director | Jounce Therapeutics, Inc. (JNCE) | 07-Jan-22 | Market Sale | 13,370 | $7.30 | $97,601.00 | (6%) 222.87K to 209.5K | 7% |
| 16-Nov-21 7:54 PM View: | Pfeffer Cary Director | Jounce Therapeutics, Inc. (JNCE) | 12-Nov-21 | Sale | -- | -- | -- | 0% 50.47K | |
| 16-Nov-21 7:57 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 12-Nov-21 | Market Sale | 1,900,000 | $8.38 | $15,922,000.00 | (29%) 6.6M to 4.7M | (3%) |
| 17-Sep-21 1:38 PM View: | Pfeffer Cary Director | Jounce Therapeutics, Inc. (JNCE) | 15-Sep-21 | Disposition (other) | -- | -- | -- | 0% 50.47K | |
| 14-Jun-21 4:19 PM View: | Third Rock Ventures Ii, L.P. 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 10-Jun-21 | Disposition (other) | 1,500,000 | -- | -- | (16%) 9.65M to 8.15M | |
| 14-Jun-21 4:23 PM View: | Pfeffer Cary Director | Jounce Therapeutics, Inc. (JNCE) | 10-Jun-21 | Disposition (other) | -- | -- | -- | 0% 35.98K | |
| 27-May-21 5:42 PM View: | Third Rock Ventures Ii, L.P. 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 25-May-21 | Market Sale | 552,520 | $8.00 | $4,420,160.00 | (6%) 9.94M to 9.39M | (2%) |
| 16-Apr-21 10:00 PM View: | Higgons John Duncan Director | Jounce Therapeutics, Inc. (JNCE) | 15-Apr-21 | Market Sale (Planned) | 200 | $10.00 | $2,000.00 | (2%) 9.91K to 9.71K | 3% |
| 31-Mar-21 8:22 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 31-Mar-21 | Option Exercise | 8,300 | $4.02 | $33,366.00 | 9% 93.58K to 101.89K | |
| 31-Mar-21 8:22 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 31-Mar-21 | Market Option Sale (Planned) | 8,300 | $10.09 | $83,747.00 | (8%) 101.89K to 93.58K | |
| 31-Mar-21 8:22 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 30-Mar-21 | Market Option Sale (Planned) | 100 | $10.00 | $1,000.00 | (< 1%) 93.69K to 93.58K | |
| 31-Mar-21 8:22 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 30-Mar-21 | Option Exercise | 100 | $4.02 | $402.00 | < 1% 93.58K to 93.69K | |
| 31-Mar-21 8:22 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 29-Mar-21 | Market Option Sale (Planned) | 5,100 | $10.09 | $51,459.00 | (5%) 98.69K to 93.58K | |
| 31-Mar-21 8:22 PM View: | Trehu Elizabeth Chief Medical Officer | Jounce Therapeutics, Inc. (JNCE) | 29-Mar-21 | Option Exercise | 5,100 | $4.02 | $20,502.00 | 5% 93.58K to 98.69K | |
| 17-Mar-21 9:15 PM View: | Higgons John Duncan Director | Jounce Therapeutics, Inc. (JNCE) | 15-Mar-21 | Market Sale (Planned) | 200 | $12.80 | $2,560.00 | (2%) 10.11K to 9.91K | 12% |
| 15-Mar-21 4:15 PM View: | Pfeffer Cary Director | Jounce Therapeutics, Inc. (JNCE) | 11-Mar-21 | Disposition (other) | -- | -- | -- | 0% 25.07K | |
| 15-Mar-21 4:15 PM View: | Third Rock Ventures Ii, L.P. 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 11-Mar-21 | Disposition (other) | 1,250,000 | -- | -- | (11%) 11.19M to 9.94M | |
| 03-Mar-21 6:09 PM View: | Pfeffer Cary Director | Jounce Therapeutics, Inc. (JNCE) | 01-Mar-21 | Sale | -- | -- | -- | 0% 9.92K | |
| 03-Mar-21 6:00 PM View: | Third Rock Ventures Ii, L.P. 10% Owner | Jounce Therapeutics, Inc. (JNCE) | 01-Mar-21 | Market Sale | 1,450,000 | $11.75 | $17,037,500.00 | (12%) 12.41M to 10.96M | (9%) |
